Dr. John Cush ✓

@RheumNow · Dallas, TX · joined 08 Apr 2011

Know-it-Now. Info on RA, Stills disease, Lupus, Gout, Pregnancy, Spondylitis, Psoriasis, Drug Safety, Rheumatology Research, Medical Education & Drug Evaluation

25 703Followers

450Following

35 442Posts total

2.9KViews on collected posts

Последние посты

Dr. John Cush ✓@RheumNow19 Sep

Join us for Tuesday Nite Rheumatology on September 22 for: Obesity Treatment & Safety Experts will tackle: • GLP-1/GIP therapies • Lifestyle & bariatric interventions • Treatment selection & safety • Cost & compounding concerns • Sarcopenia & bone health • The future of https://t

290 views · 2 likes · 2 reposts · 0 replies Open on X →

Dr. John Cush ✓@RheumNow18 Sep

🚨NEW FROM EULAR: In biologic-naive PsA, how do IL-23i, TNFi, and IL-17i compare on joint outcomes? 🦴Real-world data on TJC/SJC now available. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/MG730IkB2w https://t.co/IAz2UaD2Eg

359 views · 1 likes · 0 reposts · 0 replies Open on X →

Dr. John Cush ✓@RheumNow18 Sep

Review of HLA-B27 What’s New? HLA-B27 remains the dominant genetic link to spondyloarthritis (SpA) across the age spectrum, but B27 related clinical expression diverges between children and adults. New mechanistic data on autoreactive T cells, HLA-B27 misfolding, and gut-joint

698 views · 18 likes · 8 reposts · 0 replies Open on X →

Dr. John Cush ✓@RheumNow18 Sep

Added IVIG is Effective in Myositis A small randomized controlled trial demonstrates that intravenous immunoglobulin (IVIG) added to cortocosteroids lead to greater and faster improvements in patients with newly diagnosed idiopathic inflammatory myopathies (IIMs). https://t.co/

623 views · 9 likes · 4 reposts · 0 replies Open on X →

Dr. John Cush ✓@RheumNow15 Sep

Obesity & Inflammation https://t.co/zmZe9YJFvx 880 views · 6 likes · 2 reposts · 0 replies Open on X →

На фоне аккаунтов своего размера

5 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. доходит до меньшего числа людей, чем аккаунты того же размера.

Медианные просмотры623этот аккаунт1 020медиана для 10K–100K

Охват, %2.42%этот аккаунт4.00%медиана для 10K–100K

Вовлечённость, %1.38%этот аккаунт1.55%медиана для 10K–100K

Показатель	Этот аккаунт	Медиана для 10K–100K	Отношение
Медианные просмотры на пост	623	1 020	0.61×
Охват (просмотры ÷ подписчики)	2.42%	4.00%	0.61×
Вовлечённость	1.38%	1.55%	0.89×

Другие в этом диапазоне → Сравнить с другим аккаунтом → Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

88015 Sep

62318 Sep

698

359

29019 Sep

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.02%15 Sep

2.09%18 Sep

3.87%

0.28%

1.38%19 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.55%.

What the audience does

Likes53.7%36 in total

Reposts23.9%16 in total

Quotes3.0%2 in total

Bookmarks19.4%13 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Последние посты

На фоне аккаунтов своего размера

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Похожие аккаунты